ArticlePloS one2026
Propofol provides a significant survival advantage in sepsis-associated encephalopathy: A retrospective cohort study investigating one-year all-cause mortality.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- New trends and hotspots in Sepsis-associated encephalopathy research: a bibliometric and visualization analysis.Frontiers in aging neuroscience · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionConsidering the high incidence, mortality, and long-term effects of sepsis-associated encephalopathy (SAE), along with the availability of sedation therapy data and the significance of distress management, this study investigated the relationship between sedation therapy and one-year all-cause mortality in patients with SAE.
methodsThis retrospective cohort study utilized the Medical Information Market for Intensive Care (MIMIC-IV) database. We gathered demographic data, vital signs, laboratory test results, microbial findings, comorbidities, scoring systems, treatments administered within the first 24 hours of patient admission to the intensive care unit (ICU), and follow-up data from 24 hours after ICU admission to one year. Cox regression models were employed to evaluate the relationship between sedation therapy and one-year all-cause mortality among patients with SAE. Propensity score matching (PSM) and subgroup analyses were used to assess the robustness of the findings.
resultsFour thousand six hundred eighteen patients with SAE were enrolled, including 3,343 in the sedative group and 1,275 in the non-sedative group; additionally, 511 pairs were matched. A protective correlation was observed between propofol monotherapy and one-year all-cause mortality in patients with SAE, with hazard ratios (HRs) of 0.51 (95% confidence interval (CI), 0.40-0.65), P < 0.001. Furthermore, the interaction between propofol monotherapy and ventilation support significantly increased one-year all-cause mortality, yielding an HR of 0.70 (95% CI, 0.49-1.00) with P for interaction = 0.041. The results of PSM remained robust.
conclusionOur study indicated that compared to patients with SAE who did not receive sedation, administering propofol alone significantly reduced one-year all-cause mortality among patients with SAE. For patients undergoing ventilation support on the first day of ICU admission, the interaction between sedation therapy and ventilation support significantly influenced the one-year all-cause mortality of patients with SAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.